CD80 and neoplasm: Oral administration of FIP-fve significantly increased the tumoricidal capacity of peritoneal macrophages and tumor-specific splenocytes, and up-regulated the expression levels of MHC class I and II molecules and costimulatory molecule CD80 on peripheral blood mononuclear cell to inhibit tumor growth and angiogenesis (91).